Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.55 |
| ▸ | PRMT3 | O60678 | 8/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105029 | 1.00 | ULK1 (0.55) | ULK1PRMT3IMPDH2SMYD3ROCK2 | |
| SCHEMBL11896089 | 1.00 | ULK1 (0.55) | ULK1PRMT3IMPDH2SMYD3ROCK2 | |
| SCHEMBL14146999 | 0.88 | PRMT3 (0.60) | PRMT3IMPDH2ROCK2ROCK1GSK3B | |
| SCHEMBL14562537 | 0.88 | GSK3B (0.59) | ULK1PRMT3IMPDH2SMYD3GSK3B | |
| SCHEMBL14562538 | 0.88 | GSK3B (0.59) | ULK1PRMT3IMPDH2SMYD3GSK3B | |
| SCHEMBL1105185 | 0.88 | GSK3B (0.59) | ULK1PRMT3IMPDH2SMYD3GSK3B | |
| SCHEMBL20353540 | 0.83 | PRMT3 (0.61) | PRMT3IMPDH2GSK3BCCNE1CDK2 | |
| SCHEMBL20353543 | 0.82 | PRMT3 (0.62) | PRMT3IMPDH2CCNE1CDK2CDK5 | |
| SCHEMBL1105034 | 0.80 | IMPDH2 (0.56) | PRMT3IMPDH2ROCK2ROCK1JAK2 | |
| SCHEMBL30664127 | 0.77 | ULK1 (0.87) | ULK1ROCK2ROCK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450344-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450344-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8153656-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-8153656-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2010-01-28 | — | — | US | disclosed |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | ULK1 867/4885PRMT3 1466/4885IMPDH2 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.